Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin-associated LIM protein (ALP), encoded by the *PDLIM3* gene, is a cytoskeletal adaptor that contains both a PDZ domain and a LIM domain, allowing it to anchor and organize actin filaments within muscle cells[1][2][4]. ALP is highly expressed in heart and skeletal muscle, where it localizes primarily to Z-discs and intercalated discs, playing a crucial role in myofibrilogenesis and muscle fiber contractility[1]. It supports cross-linking of actin filaments by α-actinin-2 and is essential for correct cardiac chamber formation and function, as highlighted in knockout mouse models where its absence causes right ventricular malformations and cardiomyopathy. Structural studies show that ALP and other PDLIM family proteins function mainly as scaffolds linking cytoskeletal and membrane-associated proteins, thereby influencing subcellular localization and actin filament organization[2]. No direct drug-targeting or biomarker utility has been established for PDLIM3/ALP to date.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actin-associated LIM protein (ALP).